@article{ATM23673,
author = {Haifeng Qin and Fang Wang and Ke Wang and Hui Liu and Rui Guo and Zhen Zeng and Xin Pan and Xiaofeng Fu and Ting Zhang and Hongjun Ga},
title = {Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population},
journal = {Annals of Translational Medicine},
volume = {7},
number = {3},
year = {2019},
keywords = {},
abstract = {Targeted therapy is an important anti-cancer therapy in non-small cell lung cancer (NSCLC). Pruritus are the common side-effect with gefitinib, an anti-EGFR antibody and tyrosine-kinase inhibitor. We reported case reports to confirm the effects of aprepitant, a neurokinin receptor to management of refractory rash and pruritus in Chinese malignancy population. patients showed a rapid recovery from refractory pruritus, no adverse events occurred. Weekly follow-up visits showed the pruritus were stable and no further episodes was recorded.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/23673}
}